Publication at Faculty of Medicine in Pilsen |
2022
Abstract
The treatment of multiple sclerosis (MS) has gone through significant progress in last couple of years. Although the presence of oligoclonal bands in the liquor is one of the keys for the diagnosis of MS, the function of B lymphocytes in the pathophysiology of this disease has been long time underestimated.
Only the invention of drugs that cause B-lymphocyte depletion has demonstrated their ability to suppress disease activity of this diseases. We currently have another drug from this group called ofatumumab.
This is the first fully human monoclonal antibody available for the treatment of relapsing-remitting forms of MS. The aim of this article is to present the most recently published safety and efficacy data on ofatumumab.